Related Experiment Video
Updated: Aug 1, 2026
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Novel antioxidants zolimid and AEOL11201 ameliorate colitis in rats
S Choudhary1, A Keshavarzian, S Yong
1Department of Medicine Rush Presbyterian St Lukes Medical Center, Chicago, Illinois 60612, USA.
Abstract:
The mechanism of tissue damage in ulcerative colitis (UC) is unknown. However, recent evidence suggests that reactive oxygen species (ROS) are critical mediators of inflammation, and tissue damage in UC and antioxidants could be beneficial in the treatment of UC. Our aim was to evaluate the effects of two new antioxidants, Zolimid and AEOL11201 on experimental colitis. Antioxidants or vehicle were given to rats for five days after induction of colitis by intrarectal administration of 4% acetic acid. Severity of colitis was assessed on day 5. Zolimid and AEOL11201 significantly improved acetic acid-induced colitis. Both Zolimid and AEOL11201 significantly decreased the severity of diarrhea, and severity of macroscopic and histological changes in the colon. Both agents also significantly decreased colonic MPO levels. In conclusion, Zolimid and AEOL11201 are effective antiinflammatory agents in an animal model of colitis. Further studies are needed to evaluate their beneficial therapeutic effects in patients with UC.
Insights
New antioxidants, Zolimid and AEOL11201, effectively reduced inflammation and tissue damage in a rat model of ulcerative colitis (UC). These findings suggest potential therapeutic benefits for UC patients.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Ulcerative colitis (UC) pathogenesis involves inflammation and tissue damage, with reactive oxygen species (ROS) implicated as key mediators.
- Antioxidants show promise for managing UC by counteracting ROS-induced damage.
Purpose of the Study:
- To investigate the efficacy of two novel antioxidants, Zolimid and AEOL11201, in an experimental model of colitis.
Main Methods:
- Colitis was induced in rats using intrarectal acetic acid administration.
- Rats received either Zolimid, AEOL11201, or vehicle for five days post-induction.
- Colitis severity was assessed macroscopically, histologically, and by measuring colonic MPO levels.
Main Results:
- Both Zolimid and AEOL11201 significantly ameliorated acetic acid-induced colitis.
- These antioxidants markedly reduced diarrhea, macroscopic colonic damage, and histological alterations.
- Colonic MPO levels, an indicator of inflammation, were significantly decreased by both agents.
Conclusions:
- Zolimid and AEOL11201 demonstrate significant anti-inflammatory and therapeutic effects in a preclinical model of colitis.
- Further clinical research is warranted to explore their potential as treatments for ulcerative colitis in human patients.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
08:34Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
